Welcome to our dedicated page for SWK Holdings SEC filings (Ticker: SWKHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SWK Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SWK Holdings's regulatory disclosures and financial reporting.
SWK Holdings Corporation files its Annual Report outlining a specialty finance strategy focused on healthcare and life sciences. The company’s business now centers on its Finance Receivables segment after selling substantially all assets of its Pharmaceutical Development segment in 2025.
SWK provides royalty-backed and revenue interest financings, mainly in sub-$50 million transactions, and has funded about $876.1 million across 58 parties as of March 7, 2026. As of June 30, 2025, common equity held by non-affiliates was valued at $45,770,456, and 12,095,979 common shares were outstanding as of March 16, 2026.
The report highlights extensive risk factors, including credit losses on royalty and debt investments, heavy regulation of life sciences, dependence on third parties to market royalty-generating products, limited portfolio diversification, cybersecurity and AI-related risks, significant influence from a controlling stockholder group, and potential impacts from announced mergers.
SWK Holdings Corporation entered into a Seventh Amendment to its Credit Agreement with First Horizon Bank and other lenders. Effective February 12, 2026, the amendment revises the financial covenants and reduces the aggregate lending commitments from $10.0 million to $7.5 million.
The amendment relates to the company’s existing facility originally dated June 28, 2023, and is documented in the filed Seventh Amendment to Credit Agreement, which is incorporated by reference as an exhibit.